Adrian Hadiono, MD
Clinical Neurophysiology · Concord, NCNPI 1659733186
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,936 of the $2,246 with a category attached, or 86.2%. It is spread thinly across 22 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $843 and has fallen 89.0% since, to $93 in 2025.
Across 74 payments — averaging $30.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$482
- Biogen$357
- E.r. Squibb & Sons, L.L.C.$141
- Pfizer$113
- AstraZeneca$100
- Biohaven Pharmaceutical Holding Company Ltd.$99
- plus $953 from 16 others
What the payments were for
- Consulting fees$1507%
- Food & beverage$1,93686%
- Education$1607%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $482 |
| Biogen | 9 | $357 |
| E.r. Squibb & Sons, L.L.C. | 2 | $141 |
| Pfizer | 7 | $113 |
| AstraZeneca | 1 | $100 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $99 |
| Axsome Therapeutics, Inc. | 1 | $93 |
| Johnson & Johnson | 1 | $91 |
| Tanabe Pharma America, Inc. | 1 | $87 |
| Lilly USA, LLC | 5 | $85 |
| SK Life Science, Inc. | 3 | $81 |
| Novartis | 5 | $81 |
| EMD Serono, Inc. | 2 | $80 |
| Bristol Myers Squibb | 4 | $72 |
| TG Therapeutics, Inc. | 3 | $62 |
| Impel Pharmaceuticals Inc. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Lundbeck LLC | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 2 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $18 |
| Argenx US, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical neurophysiology providers in North Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 37 | $321,336 |
| AustedoDeutetrabenazine | 22 | $160,010 |
| IngrezzaValbenazine Tosylate | 13 | $102,270 |
| UbrelvyUbrogepant | 44 | $68,839 |
| Nurtec OdtRimegepant Sulfate | 35 | $59,322 |
| QuliptaAtogepant | 38 | $57,839 |
| Aimovig AutoinjectorErenumab-Aooe | 42 | $36,420 |
| Emgality PenGalcanezumab-Gnlm | 19 | $14,063 |
| Ajovy SyringeFremanezumab-Vfrm | 20 | $14,006 |
| Dalfampridine ErDalfampridine | 30 | $10,845 |
| EliquisApixaban | 15 | $8,972 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $8,569 |
| Gabapentin | 248 | $4,630 |
| Levetiracetam | 120 | $2,621 |
| Mycophenolate Mofetil | 20 | $2,226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $47 | $160,01022 claims |
| AbbVieUbrelvy, Qulipta | $482 | $126,67882 claims |
| PfizerNurtec Odt, Eliquis | $113 | $68,29450 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Other clinical neurophysiology in Concord
- Christopher ConnellyConcord$431
- Prabhu EmmadyConcord$54
- Muhammad ZafarDurham$144K
- Christa SwisherCharlotte$39K
- James CaressWinston Salem$24K
- Matthew LuedkeDurham$7K
- Vishal MandgeDurham$4K
- Jane BoggsWinston Salem$555
- Jennifer ZuroskyCharlotte$404
- Betty StewartHendersonville$54
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.